A more selective approach that only targets arterial wall macrophages may be warranted as the metabolic syndrome can be associated not only with functional iron deficiency (predicted to be ameliorated by hepcidin antagonism) but also with iron overload (predicted to be aggravated by systemic hepcidin inhibition). The gene discussed is HAMP; the disease is metabolic syndrome.